Managing nirmatrelvir/ritonavir during COVID-19: pharmacists’ experiences from the Perak state of Malaysia

Novel therapeutic agents for SARS-CoV-2 have emerged over time, serving to reduce the severity of the disease, admission and mortality, especially among high-risk populations. Oral nirmatrelvir/ritonavir (Paxlovid(®)) was found to reduce the risk of disease progression. Pharmacists played multiple r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chee Tao, Ong, Su Yin, Lim, Xin Jie, Chew, Lan Sim, Rajan, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589596/
https://www.ncbi.nlm.nih.gov/pubmed/36274169
http://dx.doi.org/10.1186/s40545-022-00469-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589596/
https://www.ncbi.nlm.nih.gov/pubmed/36274169
http://dx.doi.org/10.1186/s40545-022-00469-1

Ejemplares similares